Rosacea Review - Newsletter of the National Rosacea SocietyRosacea Review - Newsletter of the National Rosacea Society

Survey Shows Most Patients are Satisfied with Therapy, But More Awareness of Treatment Options is Needed

A recent National Rosacea Society (NRS) survey found that most rosacea patients were satisfied with the oral and topical prescription therapies they are using, but that individuals 60 and over were more likely to use older treatments, rather than newer products that may more effectively target specific signs and symptoms.

In the survey of 1,714 rosacea patients, 54% of those 60 and over reported that they are still using the first prescription therapy ever developed and approved for rosacea, compared to 41% of those under 60. Furthermore, 42% of respondents 60 and over had never changed their treatment regimen, compared to only 19% of those under 60.

“These findings suggest that older patients should talk with their doctors about newer therapeutic options,” said Dr. Linda Stein Gold, director of dermatology clinical research at the Henry Ford Health System. “Rosacea is now understood to include a variety of possible combinations of signs and symptoms, and there is now a range of medical therapies that will address them individually. In addition, taking more than one medication as prescribed may have a synergistic effect to achieve more successful results.”

Treatment differences between older and younger rosacea patients extended to other products as well. Respondents under 60 were more than twice as likely to be using topical ivermectin than those 60 and over (20.7% vs. 9.1%) and five times more likely to be using topical oxymetazoline (6.9% vs. 1.4%). Prescription azelaic acid foam was a frequent choice among both age ranges, with 15.1% of those under 60 and 13% of those 60 or older using the treatment. Survey participants could select more than one treatment, and about 22% of respondents said they used an over-thecounter product.

Although the onset of rosacea may often occur between the ages of 30 and 60, as a chronic condition its population impact is cumulative and highly prevalent during the elder years.

“Today’s approach to rosacea treatment is different than in the past, when there were few options in our tool kit to address the variable signs and symptoms that may be present in an individual case,” Dr. Stein Gold said. “Now that there are effective therapies available to combat each sign and symptom, it is possible to tailor treatment to the needs of each patient.”

No matter what treatment options rosacea patients reported using, they were generally happy with the results. Rated on a scale of 1 to 5, with 5 being most satisfied, almost all had weighted average satisfaction scores of 3.5 or higher, and none scored below a 3. About 56% of those surveyed said their skin was clear or almost clear on most days, 30% said their rosacea was mild, and 12% said their condition was moderate. Only 1% reported severe rosacea.

“It’s important that patients follow directions on exactly how and when to apply each medication, and use it consistently. Rosacea can often be successfully kept at bay, especially if treatment is taken exactly as prescribed,” Dr. Stein Gold said. “Not only will a partnership between a patient and their doctor produce the best results, appropriate management may help slow progression as well as maintain remission.”